NovoCure Limited (NVCR) FY2026 Q2 P&L / Income Statement

NovoCure Limited (NVCR) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

183,584,000 US dollars

Cost of revenues

41,106,000 US dollars

Gross profit

142,478,000 US dollars

Total operating costs and expenses

153,040,000 US dollars

Operating income (loss)

negative 10,562,000 US dollars

Other income (expense), net (calculated)

negative 1,890,000 US dollars

Income (loss) before income tax

negative 12,452,000 US dollars

Income tax

3,206,000 US dollars

Net income (loss)

negative 15,658,000 US dollars

UNITED STATES

102,955,000 US dollars

GERMANY

23,341,000 US dollars

FRANCE

21,347,000 US dollars

JAPAN

11,780,000 US dollars

Other international markets

18,205,000 US dollars

CHINA

5,956,000 US dollars

Research, development and clinical studies

51,448,000 US dollars

Sales and marketing

61,684,000 US dollars

General and administrative

39,908,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.